Zoltan Szallasi, Miklos Diossy, Viktoria Tisza, Hua Li, Pranshu Sahgal, Jia Zhou, Zsofia Sztupinszki, Denise Young, Darryl Nuosome, Claire Kuo, Jiji Jiang, Yongmei Chen, Reinhard Ebner, Isabell Sesterhenn, Joel Moncur, Gregory Chesnut, Gyorgy Petrovics, Gregory T Klus, Gábor Valcz, Pier Nuzzo, Dezso Ribli, Judit Börcsök, Aurél Prósz, Marcin Krzystanek, Thomas Ried, Dávid Szüts, Kinza Rizwan, Salma Kaochar, Shailja Pathania, Alan D'Andrea, István Csabai, Shib Srivast, Matthew Freedman, Albert Dobi, Sandor Spisak
We analyzed genomic data derived from the prostate cancer of African and European American men in order to identify differences that may contribute to racial disparity of outcome and that could also define novel therapeutic strategies. In addition to analyzing patient derived next generation sequencing data, we performed FISH based confirmatory studies of Chromodomain helicase DNA-binding protein 1 ( CHD1 ) loss on prostate cancer tissue microarrays. We created CRISPR edited, CHD1 deficient prostate cancer cell lines for genomic, drug sensitivity and functional homologous recombination (HR) activity analysis...
April 1, 2024: Research Square